Title variants
Languages of publication
Abstracts
Recently many investigators have found that platelet glycoprotein GP IIb/IIIa is responsible for platelet aggregation and plays a pivotal role in acute coronary thrombosis. Thus, GP IIb/IIIa antagonists may play an important role by inhibiting platelet aggregation and their binding to fibrinogen. Drugs that antagonize this binding have been developed for the treatment of thrombotic diseases and acute coronary syndrome. Now, there are three group of platelet receptor antagonists: monoclonal antibodies, synthetic peptides and non-peptide antagonists. As a result of large clinical trials the potency of those compounds in preventing of coronary thrombosis have been demonstrated. In this article molecular aspects of GP antagonists action and selected clinical trials have been presented.
Year
Volume
Issue
Pages
419-432
Physical description
Contributors
author
References
Document Type
ARTICLE
Publication order reference
T. Francuz, ul. Gliwicka 218a/1, 40-860 Katowice, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-2cffa062-97a5-3bc9-9e96-c5dcf30a3b07